De-escalation of Neoadjuvant Chemotherapy Regimens With Targeted Therapy Among HER2 Positive Patients
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Neoadjuvant therapy is currently the standard treatment process for locally advanced breast cancer, especially for human epidermal growth factor receptor 2 (HER2) positive and triple negative breast cancer, which meets the requirements of tumor ≥ 2cm and/or lymph node positive, and the guidelines recommend neoadjuvant therapy as the first choice. Chemotherapy combined with trastuzumab and pertuzumab is the standard neoadjuvant therapy for HER2 positive breast cancer patients. Taxane plus carboplatin (TCb) is the first choice of chemotherapy recommended by major guidelines; As an alternative, single drug Taxane (T) is also listed as class I recommendation in the latest CSCO guidelines, but the level of evidence is slightly insufficient. Considering the defects such as large side effects of combined chemotherapy, whether single drug chemotherapy can be used as the first choice for some people under the support of targeted drugs remains to be studied. This project plans to a cohort study, based on the large sample breast disease cohort database established by the breast center of Peking University People's Hospital, and retrospectively include the patients with clinical stage T2 and above and/or lymph node positive breast cancer who received neoadjuvant therapy (TCbHP or THP) from January 1, 2015 to December 31, 2024. Patients of the same type were prospectively included from January 1, 2025 to December 31, 2028. The effectiveness and safety of TCbHP and THP as a neoadjuvant therapy were compared.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjenci z rakiem piersi dodatnim na HER2 potwierdzonymi biopsją w Szpitalu Ludowym Uniwersytetu Peskiego
- •Nowotwór w stadium II lub III (wielkość guza T2 lub większa, i/lub zajęcie węzłów chłonnych, bez przerzutów do odległych narządów)
- •Leczenie w naszym szpitalu z dokumentacją hospitalizacji
- •Podpisana zgoda na uczestnictwo w badaniu kohortowym raka piersi
✗ Disqualifies
- •Brak pełnych danych klinicznych i patologicznych (obrazy, wyniki biopsji)
- •Rak piersi z przerzutami do odległych narządów lub obustronny rak piersi
- •Jednoczesne uczestnictwo w innych badaniach klinicznych z terapią przeciwnowotworową
- •Stosowanie schematów leczenia innych niż zaplanowany schemat neoadjuwantny
Simplified criteria — AI translation
Trial details
- Last updated (source)
- November 25, 2024
- Sex
- No restrictions
Locations (1)
Peking University People's Hospital
Beijing, China
Trial contact
yuan peng, doctor
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.